Tixupharma
Pipeline
We’re building our fundamental understanding to exploit the mechano-biostimulatory pathways and advance our core therapeutic.
Through our medical device strategy we continue to evolve into regenerative medicine with highest unmet needs and opportunities.
Mechanosensing driving-force at work
The key Mode of Action (MoA) of our pipeline consists in the stimulation of cell mechanotransduction leading to regenerative, indeed therapeutic effects. The MoA acts via microenvironmental activation of cell mechanosensors on focal adhesion machinery, which in turns evokes biomechanical cues comparable to a 'soft' tissue rehabilitation, then leading to the progressive tissue regeneration.
The stimulated mechanotransduction is assisted by ancillary anti-oxidant and pro-autophagy effects, thus leading to the progressive amelioration of chronic and degenerative disorders.